SecBot SecBot
8-K ·Filed Aug 14, 2026

OTLK

Outlook Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonmonths Processed3mo ago SEC0001104659-26-096478
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

Watch for US launch execution metrics (prescriber uptake, reimbursement codes, initial sales) in the next 2-3 quarters. The dilutive offering provides near-term liquidity but the stock will remain under pressure until LYTENAVA generates meaningful revenue. Monitor for additional capital needs or partnership announcements.

DirectionBearish
Confidencemedium
Horizonmonths

Price Chart

Loading chart...

Executive Summary

Outlook Therapeutics reported Q3 FY2026 results with net loss of $20.3M ($0.15 GAAP EPS, $0.09 adjusted) and revenue of just $9K, down from $1.5M a year ago. The company simultaneously closed a $55M dilutive public offering at $0.99/unit to fund the US launch of LYTENAVA, its only FDA-approved product. Despite the approval catalyst, the combination of near-zero revenue, ongoing losses, going-concern risk, and 30% dilution makes this a bearish event.

Key Financial Metrics

EPS
−$0.09
est −$0.07 · -28.6%
Revenue
$9.0K
est $967.0K · -99.1% · -99.4% YoY
Rating
miss

Key Facts

  • GAAP net loss of $20.3M for Q3 FY2026, essentially flat vs $20.2M in the prior-year quarter
  • Adjusted net loss (non-GAAP) of $10.9M, or $0.09 per share, vs consensus estimate of $-0.07 (miss)
  • Revenue collapsed to $9K from $1.5M a year ago, reflecting the end of initial EU launch sales
  • Cash and cash equivalents of $11.2M as of June 30, 2026, before the $51.1M net proceeds from the August offering
  • Subsequent public offering of 55.6M shares and warrants at $0.99/unit, representing ~30% dilution
  • LYTENAVA (bevacizumab-vikg) received FDA approval in July 2026; US commercial launch planned by end of calendar 2026
  • Management projects potential to exceed $500M in annual US sales by 2030, but no near-term guidance provided

Financial Impact

Dilutive offering of ~$51.1M net proceeds at $0.99/unit, representing 30% dilution; cash runway extended into Q2 2027 but going concern remains

dilutioncash positionrevenuenet loss

Risk Factors

  • Going concern risk: cash runway only into Q2 2027 even after the offering; additional capital required
  • Commercial execution risk: first-ever US launch for a company with no prior commercial experience
  • Competition from off-label Avastin and established anti-VEGF therapies (Eylea, Vabysmo, Lucentis biosimilars)
  • Potential Nasdaq delisting if stock price remains low (currently $166M market cap, offering at $0.99)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-096478
Document: tm2622399d3_8k.htm0001104659-26-096478
Document: 0001104659-26-096478-index-headers.html0001104659-26-096478
Document: 0001104659-26-096478-index.html0001104659-26-096478
Document: 0001104659-26-096478.txt0001104659-26-096478
8-K Data (Synthetic)0001104659-26-096478

Track record

37 reports on OTLK

Performance horizon

13 of 23 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 23 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Viewing No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026